Science Over Stigma: Why Legislators Must Embrace Tobacco Harm Reduction

For years, the conversation around e-cigarettes and tobacco harm reduction (THR) products has been clouded by fearmongering and persistent regulatory pushback. While millions of adult smokers have successfully used e-cigarettes and other THR products—including nicotine pouches and heat-not-burn devices—to stop smoking cigarettes, the medical community has often remained hesitant to recommend them, and policymakers have leaned toward prohibition instead.

However, a massive shift is underway that could, and should, transform how the medical community and policymakers view these innovative products. Recent research and landmark clinical data are dismantling the myths that have long driven vaping bans and misguided policies restricting use. More evidence than ever is pointing toward a future where science and research, rather than stigma, dictate public health policy—bureaucracy permitting.

A landmark article published in the Journal of the American Medical Association (JAMA), written by an International Society for Research on Nicotine and Tobacco Treatment Research Network working group, highlights the growing evidence that THR products have a key role to play in smoking cessation.

The working group anchored its conclusions in rigorous data, highlighting a Cochrane living systematic review that is updated monthly. The findings provide reputable evidence from 9 randomized clinical trials involving 2,703 participants, showing that vaping is significantly more effective at helping people quit smoking than traditional nicotine replacement therapies (NRTs) like patches, gums, and lozenges.

Crucially, the JAMA article also addressed the safety fears that frequently stall clinical recommendations, noting that “no trials to date have found evidence of serious harms from using nicotine e-cigarettes as a stop-smoking device.”

This growing collection of evidence, coupled with recent shifts in the Food and Drug Administration’s treatment of these products, signals a significant turning point for harm reduction efforts. On June 30, 2026 FDA issued a modified risk granted orders to Swedish Match USA, Inc. for 20 ZYN nicotine pouch products. For said products the agency authorized the company to market those producst with the claim, “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” Examples abound of real-world harm reduction success, but formal empirical work that is leaning overwhelmingly in one direction signals to doctors that recommending e-cigarettes to patients who want to quit smoking is backed by hard science.

For far too long, prohibition and heavy-handed government restrictions on THR products have hindered harm reduction and ignored the vital role e-cigarettes play for adult smokers trying to quit. Martin Cullip, International Fellow at the Taxpayers Protection Alliance, stated that bans and restrictions on safer alternatives to smoking can only lead to unintended consequences. “Imposing rules and regulations based on ideology and distaste for products which are in great demand risks countries losing control of their tobacco and nicotine markets entirely. The epidemic of criminality and violence happening in Australia is a testament to that.”

When policymakers rely on fear tactics rather than real-world data, they inadvertently protect the deadliest product on the market, combustible tobacco, and, unfortunately, drive consumers to black markets.

The World Health Organization (WHO) estimates that approximately one in ten tobacco products consumed globally is illicit and describes illicit tobacco trade as a major health, economic, and security concern. The WHO reported in 2025 that illicit tobacco trade accounts for approximately 11 percent of the global tobacco market. It is curious, then, that the international bureaucracy remains steadfastly opposed to allowing access to THR products.

The Centers for Disease Control and Prevention (CDC) states that cigarette smoking remains the leading cause of preventable death in the United States, responsible for more than 480,000 deaths each year. On average, smokers die approximately 10 years earlier than non-smokers. The impact of smoking extends beyond health concerns to high economic costs, amounting to more than $600 billion annually in the U.S. Legalizing reduced-risk products would dramatically reduce death rates and bolster economic growth—not to mention tax revenues.

The real-world evidence demonstrates that harm reduction products offer a significant public health advantage by delivering nicotine without the harmful chemicals generated by traditional cigarettes. Recent research clearly debunks myths that equate vaping risks with smoking, Legislators must respond to this growing body of clinical evidence by moving away from ineffective prohibitionist policies and toward sensible science-based policies. Millions of lives depend on policymakers rejecting heavy-handed restrictions.